Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M

PartnershipPositive

AI Analysis

Summary

Zealand Pharma sold milestone and royalty rights for its polycythemia vera drug candidate to Royalty Pharma for up to $100M. Jefferies analysts suggest the deal indicates potential undervaluation of the asset's market potential.

Outcome Details

Zealand Pharma sold milestone and royalty rights to polycythemia vera drug candidate to Royalty Pharma for up to $100M

Importance:6/10

Sentiment:

0.60

partnershiproyalty_dealrare_diseasepolycythemia_veramonetization

Related Companies

$ZEAL $RPRX

Read the original article

Published by BioSpace on August 13, 2026 11:49 AM

Read Original